The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Cholesterol lowering involving different therapies improves the clinical outcome of patients. To define the underlying pathomechanism, we studied whether treatment with statins was associated with changes in blood thrombogenicity, endothelial dysfunction and soluble adhesion molecule levels. Fifty hypercholesterolemic patients were treated with pravastatin (40 mg/day, n=24) or simvastatin (20 mg/day,...
Background: Lowering cholesterol (C) decreases platelet reactivity in coronary disease (CAD) patients, but its effect on non-CAD patients has not been previously described.Methods: We prospectively studied 40 stable patients with untreated LDL-C > 145 mg/dl. CAD patients received Pravastatin (Prav), and non-CAD patients were randomized to Prav vs. Placebo (double-blind). All patients were on...
Rapamycin is a macrolide antibiotic with immunosuppresant, antiproliferative and antimigratory activity on smooth muscle cells. We previously showed that i.m. administration of Rapamycin inhibits neointima formation 4-weeks after PTCA in the pig coronary model and its effect seems mediated by the induction of the cell cycle inhibitor p27kip1. We now report the effects of 4 different oral dosages...
Lipid reduction improves clinical outcome of CAD patients despite minor angiographic plaque regression. Normalization of endothelial function and plaque stabilization are two of the proposed mechanisms. We hypothesize that lipid reduction modulates blood thrombogenicity. Blood thrombogenicity was measured as thrombus formation (THR) in an ex vivo perfusion chamber. Hyperlipidemic patients (10...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.